



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 March 2023
EMA/898158/2022
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 20-23 February 2023

During its February 2023 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME which were denied. The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union






Eligibility denied

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Herbal Medicinal Product	Pain	Treatment of chronic non-cancer pain	Nonclinical + Clinical exploratory	SME
Biological Medicinal Product	Neurology	Treatment of Huntington's disease	Nonclinical + Clinical exploratory	SME

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of PRIME eligibility recommendations adopted by 23 February 2023

■ Granted ■ Denied ■ Out of scope* ■ Withdrawn



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.